|
17-phenyl trinor Prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide) is sold under the Allergan trade name Bimatoprost and is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug.1 Investigations in our lab have shown that Bimatoprost is converted by an amidase enzymatic activity in the bovine and human cornea to yield the corresponding free acid, with a conversion rate of about 40 µg/g corneal tissue/24 hours.2 The free acid, 17-phenyl trinor PGF2α, is a potent FP receptor agonist.3,4 In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity.
|
|
1
Woodward, D.F., Krauss, A.H., Chen, J., et al. The pharmacology of Bimatoprost (Lumigan™). Survey of Ophthalmology 45 S337-S345 (2001).
2
Maxey, K.M., Johnson, J., Camras, C.B., et al. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Survey of Ophthalmology 47(4) 34-40 (2002).
3
Balapure, A.K., Rexroad, C.E., Kawada, K., et al. Structural requirements for prostaglandin analog interaction with the ovine corpus luteum prostaglandin F2α receptor. Biochem Pharmacol 38 2375-2381 (1989).
4
Lake, S., Gullberg, H., Wahlqvist, J., et al. Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor. FEBS Lett 355 317-325 (1994).
|